Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Dividend Payments (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Preferred Dividend Payments for 4 consecutive years, with $2.2 million as the latest value for Q1 2026.

  • Quarterly Preferred Dividend Payments changed N/A to $2.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Jan 2026, up 127.57% year-over-year, with the annual reading at $1.1 million for FY2025, 55.13% down from the prior year.
  • Preferred Dividend Payments for Q1 2026 was $2.2 million at PharmaCyte Biotech, up from $96639.0 in the prior quarter.
  • The five-year high for Preferred Dividend Payments was $3.3 million in Q3 2023, with the low at -$9.5 million in Q2 2024.
  • Average Preferred Dividend Payments over 4 years is -$175819.4, with a median of $636343.5 recorded in 2023.
  • Peak annual rise in Preferred Dividend Payments hit 24.35% in 2024, while the deepest fall reached 79.04% in 2024.
  • Over 4 years, Preferred Dividend Payments stood at $586886.0 in 2023, then fell by 24.35% to $443958.0 in 2024, then plummeted by 78.23% to $96639.0 in 2025, then soared by 2181.33% to $2.2 million in 2026.
  • According to Business Quant data, Preferred Dividend Payments over the past three periods came in at $2.2 million, $96639.0, and $443958.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.